KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aquestive Therapeutics (AQST) Enterprise Value (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Enterprise Value data on record, last reported at -$121.2 million in Q4 2025.

  • For Q4 2025, Enterprise Value fell 69.36% year-over-year to -$121.2 million; the TTM value through Dec 2025 reached -$121.2 million, down 69.36%, while the annual FY2025 figure was -$121.2 million, 69.36% down from the prior year.
  • Enterprise Value reached -$121.2 million in Q4 2025 per AQST's latest filing, up from -$129.1 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$14.7 million in Q1 2022 and bottomed at -$129.1 million in Q3 2025.
  • Average Enterprise Value over 5 years is -$50.6 million, with a median of -$29.6 million recorded in 2021.
  • Peak YoY movement for Enterprise Value: skyrocketed 48.31% in 2022, then tumbled 300.56% in 2024.
  • A 5-year view of Enterprise Value shows it stood at -$28.0 million in 2021, then grew by 2.68% to -$27.3 million in 2022, then increased by 12.47% to -$23.9 million in 2023, then plummeted by 199.71% to -$71.5 million in 2024, then tumbled by 69.36% to -$121.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Enterprise Value were -$121.2 million in Q4 2025, -$129.1 million in Q3 2025, and -$60.5 million in Q2 2025.